Android app on Google Play

VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)

December 10, 2012 9:10 AM EST Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $3.78 --0%

Rating Summary:
    4 Buy, 7 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 12 | Down: 11 | New: 37
Trade VVUS Now!
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is ticking higher in early trading Monday following reports that Qsymia prescriptions rose following the Thanksgiving holiday.

According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.

BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.

Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment